Forest and Ironwood file IBS/constipation drug linaclotide for US approval
This article was originally published in Scrip
Executive Summary
Ironwood Pharmaceuticals and its US partner Forest Laboratories have submitted the once-daily oral peptide treatment linaclotide to the FDA for US approval to treat irritable bowel syndrome with constipation (IBS-C) and chronic constipation.